



Title	Combined exposure to phthalate esters and phosphate flame retardants and plasticizers and their associations with wheeze and allergy symptoms among school children
Author(s)	Araki, Atsuko; Ait Bamai, Yu; Bastiaensen, Michiel; Van den Eede, Nele; Kawai, Toshio; Tsuboi, Tazuru; Miyashita, Chihiro; Itoh, Sachiko; Goudarzi, Homan; Konno, Satoshi; Covaci, Adrian; Kishi, Reiko
Citation	Environmental Research, 183, 109212 <a href="https://doi.org/10.1016/j.envres.2020.109212">https://doi.org/10.1016/j.envres.2020.109212</a>
Issue Date	2020-04
Doc URL	<a href="http://hdl.handle.net/2115/87339">http://hdl.handle.net/2115/87339</a>
Rights	© 2020 This manuscript version is made available under the CC-BY-NC-ND 4.0 license <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Rights(URL)	<a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Type	article (author version)
File Information	25_Environ Res.pdf



[Instructions for use](#)

1 **Combined exposure to phthalate esters and phosphate flame retardants and plasticizers**  
2 **and their associations with wheeze and allergy symptoms among school children**

3  
4 Atsuko Araki<sup>a</sup>, Yu Ait Bamai<sup>a</sup>, Michiel Bastiaensen<sup>b</sup>, Nele Van den Eede<sup>b</sup>, Toshio Kawai<sup>c</sup>, Tazuru  
5 Tsuboi<sup>c</sup>, Chihiro Miyashita<sup>a</sup>, Sachiko Itoh<sup>a</sup>, Houman Goudarzi<sup>d, e</sup>,  
6 Satoshi Konno<sup>e</sup>, Adrian Covaci<sup>b</sup>, Reiko Kishi<sup>a\*</sup>

7  
8 <sup>a</sup> Hokkaido University, Center for Environmental and Health Sciences, Kita 12, Nishi 7, Kita-ku  
9 Sapporo 060-0812, Japan

10 <sup>b</sup> Toxicological Center, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium

11 <sup>c</sup> Osaka Occupational Health Service Center, Japan Industrial Safety and Health Association, 2-  
12 3-8, Tosabori, Nishi-ku, Osaka 550-0001, Japan

13 <sup>d</sup> Center for Medical Education and International Relations, Faculty of Medicine and Graduate  
14 School of Medicine, Hokkaido University, Sapporo, Japan Kita 15, Nishi 7, Kita-ku, Sapporo,  
15 060-8638 Japan

16 <sup>e</sup>-Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine,  
17 Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-0815 Japan

18  
19  
20 \*Corresponding author: Reiko Kishi, MD, PhD, MPH

21 Hokkaido University Center for Environmental and Health Sciences,

22 Kita 12, Nishi 7, Kita-ku, Sapporo 060-0812, Japan

23 Phone: +81-11-706-4746

24 Fax: +81-11-706-4725

25 E-mail: [rkishi@med.hokudai.ac.jp](mailto:rkishi@med.hokudai.ac.jp)

26

27

28 **Declarations of interest:** none.

29 **Abstract:**

30 **BACKGROUND:** Phthalate esters and phosphate flame retardants and plasticizers (PFRs) are  
31 both used as plasticizers and are commonly detected in indoor environments. Although both  
32 phthalates and PFRs are known to be associated with children’s wheeze and allergic symptoms,  
33 there have been no previous studies examining the effects of mixtures of these exposures.

34 **OBJECTIVES:** To investigate the association between exposure to mixtures of phthalate esters  
35 and PFRs, and wheeze and allergic symptoms among school-aged children.

36 **METHODS:** A total of 128 elementary school-aged children were enrolled. Metabolites of 3  
37 phthalate esters and 7 PFRs were measured in urine samples. Parent-reported symptoms of  
38 wheeze, rhinoconjunctivitis, and eczema were evaluated using the International Study of  
39 Asthma and Allergies in Childhood (ISAAC) questionnaire. In the primary model, we created a  
40 phthalate ester and PFR mixture exposure index, and estimated odds ratios (ORs) using  
41 weighted quantile sum (WQS) regression and quantile g (qg)-computation. The two highest  
42 chemicals according to qg-computation weight %s were combined to create a combination  
43 high × high exposure estimate, with ORs calculated using the “low × low” exposure group as  
44 the reference category. Concentrations of each metabolite were corrected by multiplying this  
45 value by the sex- and body size-Standardised creatinine concentration and dividing by the  
46 observed creatinine value. All models were adjusted for sex, grade, dampness index and  
47 annual house income.

48 **RESULTS:** The odds ratio of rhinoconjunctivitis for the association between exposure to  
49 chemical mixtures according to the WQS index positive models was; OR = 2.60 (95%  
50 confidence interval [CI]: 1.38-5.14). However, wheeze and eczema of the WQS index positive  
51 model, none of the WQS index negative models or qq-computation result yielded statistically  
52 significant results. Combined exposure to the two highest WQS weight %s of “high-high”  
53 ΣTCIPP and ΣTPHP was associated with an increased prevalence of rhino-conjunctivitis, OR =  
54 5.78 (1.81 – 18.43) to the “low × low” group.

55 **CONCLUSIONS:** Significant associations of mixed exposures to phthalates and PFRs and  
56 increased prevalence of rhinoconjunctivitis was found among elementary school-aged  
57 children in the WQS positive model. Mixed exposures were not associated with any of allergic  
58 symptoms in the WQS negative model or qq-computation approach. However, the combined  
59 effects of exposure to two PFRs suggested an additive and/or multiplicative interaction,  
60 potentially increasing the prevalence of rhinoconjunctivitis. A further study with a larger  
61 sample size is needed to confirm these results.

62

63 **Keywords**

64 Phosphate flame retardant and plasticizers, Phthalate ester, Allergy, Exposure to mixtures,  
65 Combined exposure, Children

## 66 1. Introduction<sup>1</sup>

67 Phthalate esters are a class of chemicals predominantly used as plasticizers. Di(2-ethylhexyl)  
68 phthalate (DEHP) and butyl benzyl phthalate (BBzP) are used in polychlorinated chemicals,  
69 which are found in various plastic products, toys, food containers, and housing materials,  
70 whereas di-*n*-butyl phthalate (DnBP) and di-*i*-butyl phthalate (DiBP) are used in personal care  
71 products and fragrances (Ait Bamai et al. 2014). Organophosphate triesters, also referred to as  
72 phosphorus flame retardants and plasticizers (PFRs), are a class of chemicals predominantly  
73 used as additives in flame retardants and plasticizers. Polyurethane foam, thermoplastics,  
74 resins, polyvinylchloride, synthetic rubbers, and textiles are some of the major products that  
75 contain tri-*n*-butyl phosphate (TNBP), tris (2-chloroethyl) phosphate (TCEP), tris(1-chloro-*iso*-  
76 propyl) phosphate (TCIPP), tris (1,3-dichloro-2-propyl) phosphate (TDCIPP), and triphenyl  
77 phosphate (TPHP) (Stapleton et al. 2009; van den Eede et al. 2011). TNBP, TPHP, and tricresyl

---

<sup>1</sup> **Abbreviations:** 3-HO-TBOEP: bis(2-butoxyethyl) 3-hydroxy-2-butoxyethyl phosphate, 3-HO-TPHP: 3-hydroxyphenyl diphenyl phosphate, 4-HO-DPHP: 4-hydroxyphenyl diphenyl phosphate, 4-HO-TPHP: 4-hydroxyphenyl diphenyl phosphate, 5-HO-EHDPHP: 5-hydroxy-2-ethylhexyl diphenyl phosphate, BBOEHEP: bis(2-butoxyethyl) 2-hydroxyethyl phosphate, BBOEP: bis(2-butoxyethyl) phosphate, BBzP: butyl benzyl phthalate, BCIPHIPP: bis(1-chloro-2-propyl) 1-hydroxy-2-propyl phosphate, BCIPP: bis(1-chloro-2-propyl) phosphate, BDCIPP: bis(1,3-dichloro-2-propyl) phosphate, DEHP: Di(2-ethylhexyl) phthalate, DiBP: di-*i*-butyl phthalate, DnBP: di-*n*-butyl phthalate, DNBP: dibutyl phosphate, DPHP: diphenyl phosphate, EHPHP: 2-ethylhexyl phenyl phosphate, MBzP: mono benzyl phthalate, MECPP: mono-(2-ethyl-5-carboxypentyl) phthalate, MEHP: mono(2-ethylhexyl) phthalate, MEOHP: mono-(2-ethyl-5-oxohexyl) phthalate, MiBP: mono-*i*-butyl phthalate, MnBP: mono-*n*-butyl phthalate, PFR: phosphate flame retardant, TBOEP: tris (2-butoxyethyl) phosphate, TCEP: tris (2-chloroethyl) phosphate, TCIPP: tris(2-chloro-*iso*-propyl) phosphate, TDCIPP: tris (1,3-dichloro-2-propyl) phosphate, TMPP: tricresyl phosphate, TNBP: tri-*n*-butyl phosphate, TPHP triphenyl phosphate, WQS: weighted quantile sum

78 phosphate (TMPP) are also used as lubricants, and tris (2-butoxyethyl) phosphate (TBOEP) is  
79 often used in floor coverings, and as a plasticizer in floor finishing products and floor polish  
80 (Kajiwara et al. 2011). 2-Ethylhexyl diphenyl phosphate (EHDPHP) is also used as a flame  
81 retardant and plasticizer in PVC materials (Ballesteros-Gómez et al. 2015). Both phthalates and  
82 PFRs are used as additives in flame retardants, plasticizers, and a variety of consumer products,  
83 such as building materials, floor and wall materials, textiles, furniture, electronic equipment,  
84 rubber products, textile coatings, polyurethane foam plastics, children's toys, and food  
85 packaging materials (Ait Bamai et al. 2014; Ballesteros-Gómez et al. 2015; Kajiwara et al. 2011).  
86 Phthalates and PFRs are not chemically bonded to the products they are used in, and can  
87 migrate, leach, and evaporate into the environment (Luongo and Östman 2016). Previous  
88 studies involving simultaneous measurements of phthalates and PFRs in house dust suggest  
89 that they can both be commonly found in indoor environments (Kanazawa et al. 2010; Kishi et  
90 al. 2017; Luongo and Östman 2016), with inhabitants potentially exposed through dust  
91 ingestion, airborne particle and gas inhalation, and dermal contact. In previous studies, higher  
92 concentrations of DEHP, BBzP, and DiBP were observed with the use of PVC materials, and  
93 DEHP and TDCIPP were detected in carpet materials (Ait Bamai et al. 2014; Bi et al. 2018).  
94 These results suggest that phthalates and PFRs share the same exposure source, and therefore  
95 humans are exposed to both chemicals at the same time.

96 Recently, several studies have reported on potential health concerns related to

97 exposure to phthalates and PFRs, including asthma and allergies in cross-sectional studies (Ait  
98 Bamai et al. 2016; Ait Bamai et al. 2014; Bekö et al. 2015; Bi et al. 2018; Bornehag et al. 2004;  
99 Callesen et al. 2014), as well as prospective birth cohorts (Just et al. 2012; Ku et al. 2015;  
100 Whyatt et al. 2014). The results from these studies were generally consistent in their reported  
101 associations for phthalate levels in house dust or heating, ventilation, and air conditioning  
102 filter dust (Ait Bamai et al. 2016; Ait Bamai et al. 2014; Bekö et al. 2015; Bornehag et al. 2004),  
103 but reported inconsistent associations between urinary phthalate metabolite levels and  
104 asthma and allergies (Callesen et al. 2014; Just et al. 2012; Ku et al. 2015; Whyatt et al. 2014).  
105 Compared to phthalates, there have been fewer studies examining the association between  
106 PFRs and asthma and allergies. We have conducted two cross-sectional studies, and reported  
107 that increasing levels of TCIPP, TDCIPP, and TNBP in house dust, as well as their urinary  
108 metabolites, were associated with increased risk of eczema and rhinoconjunctivitis (Araki et  
109 al. 2018; Araki et al. 2014). Another study is nested case-control study, which found no  
110 difference of PFRs levels in dust collected from asthma case and control children's mattress  
111 (Canbaz et al. 2016). Several different mechanisms may underline these findings, although  
112 these are not well understood. Previous experimental studies suggested that these chemicals  
113 act as ligands of receptors involved in allergenic pathology, as adjuvants that contribute to  
114 allergies, or have immunotoxic properties that affect dendritic cells (Canbaz et al. 2017;  
115 Nishioka et al. 2012; Tanaka et al. 2013). Experimental studies of these chemicals have also

116 yielded results suggesting altered immune responses (Canbaz et al. 2017; Killilea et al. 2017;  
117 Krivoshiev et al. 2018b). In addition, cross-sectional studies suggested that phthalates and  
118 PFRs increase oxidative stress (Ait Bamai et al. 2019; Lee et al. 2019; Rocha et al. 2017), which  
119 would lead to inflammation (Benjamin et al. 2017; Ito et al. 2007)

120 Humans are exposed to many chemicals at the same time, and health risk assessment for  
121 combined exposure to multiple chemicals is a current topic in the World Health Organisation's  
122 International Programme on Chemical Safety (Meek et al. 2011). However, all the  
123 aforementioned previous studies examined associations between allergies and single chemical  
124 exposure, with each agent analysed separately. Multivariate adjustment, achieved by including  
125 several chemicals in the same model, would hypothetically provide independent associations  
126 between each exposure and the relevant outcome. However, if the levels of phthalates and  
127 PFRs are correlated with each other, it is not ideal to include these chemicals in the same  
128 logistic regression model, as multicollinearity tends to inflate the standard errors of the  
129 estimated regression coefficients. Moreover, the combined exposure effect cannot be  
130 examined by the multivariable adjustment model. To date, there have been no published  
131 studies reporting on mixtures or combinations of phthalates and PFRs, and their association  
132 with asthma and allergies among children.

133 The major aim of this study is to find the association between mixtures of phthalate esters  
134 and PFRs levels and the prevalence of allergies in children. We hypothesised that mixtures of

135 chemicals would increase the prevalence of wheeze, rhinoconjunctivitis, and eczema.

136

## 137 **2. Methods**

### 138 *2.1 Study participants*

139 This study was conducted among elementary school children in Sapporo, Japan, with data  
140 collected as previously described (Ait Bamai et al. 2016; Araki et al. 2018). Briefly, an initial  
141 cross-sectional study was conducted in Sapporo city in 2008. A questionnaire was distributed  
142 to 6,393 school children from 12 public elementary schools. Of the 4,408 students who  
143 responded to the questionnaire, 951 (from 832 families) were interested to participate in a  
144 home survey that environmental measurements in the following calendar year. In 2009 and  
145 2010, 681 families with children who were still attending the same elementary school as in  
146 2008 were contacted for a home visit. Children who transferred to different schools, including  
147 junior high schools, were excluded. Through this selection procedure, we successfully visited  
148 a total of 128 homes. The other families were unwilling to participate, did not respond, or were  
149 unable to arrange their schedules for a home visit. Overall participation proportion in this  
150 study to primary questionnaire survey was 2.9%.

151

### 152 *2.2 Questionnaire*

153 Information on the exposure assessment, including the collection of children's urine, was also

154 previously reported (Ait Bamai et al. 2016; Araki et al. 2018). Briefly, parents filled out the  
155 International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire (Beasley 1998).  
156 The study investigators then defined participants for wheeze, allergic rhinoconjunctivitis, and  
157 eczema based on “yes” responses to descriptions of each symptom by ISAAC (Beasley 1998).  
158 We classified participants as having wheeze if their parents answered ‘Yes’ to the following  
159 question: ‘Has your child had wheezing or whistling in the chest in the last 12 months?’ Allergic  
160 rhinoconjunctivitis was defined by the ‘Yes’ to both of following questions: (a) ‘Has your child  
161 had a problem with sneezing, or a runny/blocked nose in the absence of a cold or flu in the  
162 last 12 months?’ and (b) ‘Has this nose problem been accompanied by itchy, watery eyes?’  
163 Eczema was defined by the ‘Yes’ to all of following questions: (a) ‘Has your child had an itchy  
164 rash that has appeared and disappeared for at least 6 months?’, (b) ‘Have the aforementioned  
165 itchy rashes appeared at any time during the last 12 months?’, and (c) ‘Have the  
166 aforementioned itchy rashes affected one or several of the following areas: the folds of the  
167 elbows, the back of knees, the front of the ankles, the underside of the buttocks, or the areas  
168 around the neck, ears, or eyes?’

169           The questionnaire also included information on potential confounding factors such as  
170 the child’s sex, school grade, and household income. The dampness index was generated by  
171 summing the number of the signs of dampness-related problems observed in each dwellings,  
172 including condensation (yes/no), mouldy odour (yes/no), visible mould (yes/no), high humidity

173 in the bathroom (yes/no), and problems with water leakage within the past 5 years (yes/no),  
174 for a possible score range of 0–5 (Kishi et al. 2009; Saijo et al. 2004).

175

### 176 *2.3 Urinary measurement of phthalate esters and PFR metabolites*

177 Details on the collection of urine samples have been reported elsewhere (Ait Bamai et al. 2015).

178 Briefly, on the day of the home visit, morning spot urine was collected by parents in a  
179 polypropylene container and refrigerated until our visit. Each urine sample was dispensed into  
180 a stoppered glass test tube cleaned with acetone on the day of the urine collection and stored  
181 at –20°C until the day of analysis.

182 Details of the analytical procedures for the urinary phthalate esters and PFR  
183 metabolites have also been described elsewhere (Ait Bamai et al. 2015; Araki et al. 2018;  
184 Bastiaensen et al. 2019). Six urinary phthalate metabolites were measured by GC-MS/MS:  
185 mono-n-butyl phthalate (MnBP), mono-i-butyl phthalate (MiBP), mono benzyl phthalate  
186 (MBzP), mono(2-ethylhexyl) phthalate (MEHP), mono-(2-ethyl-5-oxohexyl) phthalate  
187 (MEOHP), and mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP). Fourteen urinary PFR  
188 metabolites were measured by LC-MS/MS: bis(2-butoxyethyl) phosphate (BBOEP), dibutyl  
189 phosphate (DNBP), bis(2-butoxyethyl) 2-hydroxyethyl phosphate (BBOEHEP), bis(1-chloro-2-  
190 propyl) phosphate (BCIPP), bis(1-chloro-2-propyl) 1-hydroxy-2-propyl phosphate (BCIPHIPP),  
191 bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), diphenyl phosphate (DPHP), 4-hydroxyphenyl

192 diphenyl phosphate (4-HO-DPHP), bis(2-butoxyethyl) 3-hydroxy-2-butoxyethyl phosphate (3-  
193 HO-TBOEP), 4-hydroxyphenyl diphenyl phosphate (4-HO-TPHP), 3-hydroxyphenyl diphenyl  
194 phosphate (3-HO-TPHP), 5-hydroxy-2-ethylhexyl diphenyl phosphate (5-HO-EHDPHP), 2-  
195 ethylhexyl phenyl phosphate (EHPHP) and TCEP. For concentrations lower than the limit of  
196 quantification (LOQ), a detection frequency times LOQ value was assigned (James et al. 2002).  
197 Creatinine levels in urine were determined using an enzyme-linked immunosorbent assay at  
198 SRL, Inc. (Tokyo, Japan).

199 The standardised creatinine-corrected concentrations were calculated as  
200 recommended in a previous report with modification (O'Brien et al. 2016). First, we calculated  
201 the reference creatinine concentration using the individual creatinine clearance and fitted the  
202 standardised creatinine corrected concentration according to the following equations.

203 Male (height: 90–168 cm):  $CE \text{ (mg/day)} = Ht (6.265 + 0.0564 (Ht - 168))$  Eq.(1)

204 Female (height: 90–172 cm):  $CE \text{ (mg/day)} = 2.045 \exp[0.01552(Ht - 90)]$  Eq.(2)

205 Where CE is the creatinine clearance rate estimated as described previously (Mage et al. 2008).

206 Ht is the height of each child. For a child, the average urine volume is 1 mL/kg/h.

207 The reference creatinine concentration was calculated according to the following  
208 equation:

209 Reference Creatinine (mg/L) =  $CE \text{ (mg/day)} \times 1000 \text{ (mL)} / (1 \text{ mL} \times Wt \text{ (kg)} \times 24 \text{ (h)})$   
210 Eq.(3)

211 Where  $W_t$  is the weight of an individual child.

212 Finally, the standardised creatinine-corrected concentration of each metabolite was calculated  
213 by fitting to Eq.(4).

$$\text{Standardised creatinine corrected concentration} = \frac{\text{Reference Creatinine}}{\text{Observed Creatinine}} \quad \text{Eq.(4)}$$

216

#### 217 *2.4 Data analysis*

218 Urinary phthalate and PFR metabolite levels were converted to molar concentrations (nM).

219 The metabolites of DBP, DEHP, TBOEP, TCIPP and TPHP were combined into the sum of their  
220 individual concentrations, as  $\Sigma\text{DBP}$  (MnBP and MiBP),  $\Sigma\text{DEHP}$  (MEHP, MEOHP, and MECPP),  
221  $\Sigma\text{TBOEP}$  (BBOEP, 3-HO-TBOEP, and BBOEHEP),  $\Sigma\text{TCIPP}$  (BCIPP and BCIPHIPP), and  $\Sigma\text{TPHP}$  (DPHP  
222 and 4-HO-DPHP). Correlations between each compound were analyzed by Spearman's rho.

223 For the primary analysis, we used weighted quantile sum (WQS) regression models to  
224 examine the association between mixtures of chemicals and asthma and allergies. WQS is a  
225 method for combining highly correlated exposures into one index, to estimate the association  
226 between a chemical mixture and an outcome of interest (Carrico et al. 2015; Gennings et al.  
227 2010; Romano et al. 2018). The WQS estimates the effect of the mixture as a whole and  
228 calculates the impact of a single-quantile increase. This model is advantageous because it is  
229 simple to implement (Keli et al., 2019). The WQS regression model was used to calculate a

230 weighted linear index by grouping different chemicals into ordinal quantile variables that  
231 represented the associations of a mixture of all chemicals with single health outcomes. The  
232 WQS index was created with quartiles of chemical levels, and estimated empirical weights for  
233 each chemical were included in the index. WQS assumes inference in a single direction or  
234 'directional homogeneity' assumption. Both positive and negative associations were examined  
235 for WQS. Assuming directional homogeneity, the model would be equivalent to a generalised  
236 linear model. However, chemicals with opposite associations cannot be combined into a single  
237 exposure index (Carrico et al. 2015; Romano et al. 2018). Thus, a quantile-based g-  
238 computation (qg-computation) approach (Keil et al. 2019) was used additionally to estimate  
239 simultaneously the effects of a single-quantile exposure in both directions. The qg-  
240 computation was implemented based on a generalisation of the WQS regression, which  
241 estimates the expected ability of a change in one outcome to increase all exposures in the  
242 mixture by one quantile (Keil et al. 2019). The qg-computation also allows a valid inference  
243 regarding the contribution of an individual component to the mixture, even in the absence of  
244 directional homogeneity. The Standardised creatinine-corrected concentrations of 3  
245 phthalates and 6 PFRs were introduced into the WQS and qg-computation models, and each  
246 model was calculated using chemical level quartiles and 200 bootstrap runs.

247 Individual chemical models were also examined, and ORs (95% CI) were obtained  
248 using the 1<sup>st</sup> tertile as the reference category. If the WQS regression model was statistically

249 significant, then combinations of two chemicals were modelled to examine the interactions as  
250 secondary analyses. We selected the two chemicals with the two highest individual weights in  
251 the qg-computation to examine combinations of two chemicals. Each chemical was divided  
252 into tertiles: 1st and 2nd tertile to low and 3rd tertile to high concentrations, and chemical  
253 pairs were combined into “low × low”, “low × high”, “high × low”, and “high × high” categories.  
254 Logistic regression models were then used to obtain odds ratios (ORs) and 95% confidence  
255 intervals (CIs) for each combination, with “low × low” as the reference category.

256           Each model was adjusted for sex, grade, annual household income included taxes  
257 (coded as 1: <3 million Japanese yen, 2: 3-5 million Japanese yen, 3: 5-8 million Japanese yen,  
258 4: >8 million Japanese yen; modelled as an ordinal variable), and dampness index (0-5, ordinal  
259 variable) based on *a priori* evidence determined from previous studies (Ait Bamai et al. 2016;  
260 Araki et al. 2018). The mean value of annual household income (2.92 million yen) was assigned  
261 to missing values (14.8%).

262           Statistical analyses were performed in SPSS (Windows version 26.0J). The WQS model  
263 was performed using the gWQS package (version 2.0.0) (Carrico et al. 2015), and qg-  
264 computation was performed using the qgcomp package (version 1.3.0) (Keil et al. 2019), with  
265 R studio (R version 3.6.1). A two-sided p-value <0.05 was considered statistically significant.

266

267 *2.5 Ethics*

268 All parents of the study participants provided written informed consent. The study protocol  
269 was approved by the ethics board for epidemiological studies at Hokkaido University Graduate  
270 School of Medicine and Hokkaido University Center for Environmental and Health Sciences.

271

### 272 **3. Results**

273 Participant characteristics are shown in Table 1. Of the 128 participants, 53.1% were boys, and  
274 all children were in grades 2 to 6 (age range: 7–12 years). The numbers of children with wheeze,  
275 rhinoconjunctivitis, and eczema were 29 (22.7%), 47 (36.7%), and 36 (28.1%), respectively.  
276 Seventy-two children (56.3%) had at least one of the above mentioned symptoms (one or  
277 more symptoms, hereafter).

278 The distributions of urinary phthalate and PFR concentrations in nM and nmol/g  
279 standardised creatinine are shown in Table 2 and ng/mL in Supplemental table S2. Among all  
280 chemicals, the level of  $\Sigma$ DEHP was the highest (median value of 441 nM), followed by  $\Sigma$ DBP  
281 (236 nM). The levels of PFRs were approximately 100x lower than phthalates, with the highest  
282 concentration observed for  $\Sigma$ TPHP (2.13 nM) followed by  $\Sigma$ TBOEP (1.88 nM). DNBP was only  
283 detected in 8.3% of samples, and was thus excluded from further analysis. The correlations  
284 between chemicals ranged from Spearman's  $\rho$  of 0.01 to 0.624, as shown in Supplemental  
285 Table S1.

286 The results of mixed chemical models, analysed by WQS and qq-computation, are

287 shown in Table 3. For one quartile change in the WQS index increased the ORs (95% CIs) for  
288 wheeze: 1.52 (0.67 – 3.50), rhinoconjunctivitis: 2.60 (1.38 – 5.14), and eczema: 1.91 (0.99 –  
289 3.85) in the positive model. None of the negative WQS and qg-computation models were  
290 statistically significant. The individual weights for each chemical mixture component, as  
291 determined by the qg-computation approach, are shown in Figure 1. For rhinoconjunctivitis,  
292 the chemicals that showed the highest weight (%) in the positive direction were ΣTCIPP (35.0%)  
293 and ΣTPHP (24.9%). For eczema, the highest weights (%) were observed for 5-HO-EHDPPH  
294 (45.4%) and BDCIPP (42.7%).

295         The OR and 95% CI of single chemicals before combining 2<sup>nd</sup> and 3<sup>rd</sup> categories  
296 compared to the lowest category of phthalates and PFR were calculated, as shown in Table 4.  
297 For rhinoconjunctivitis, the 2<sup>nd</sup> and 3<sup>rd</sup> tertile of BDCIPP were associated with a significantly  
298 higher ORs of 2.95 (1.04-8.37) and 2.93 (1.04-8.28), respectively, relative to the 1<sup>st</sup> tertile, with  
299 a significant p-for trend of 0.045. The 3<sup>rd</sup> tertile of ΣTCIPP was associated with a significantly  
300 higher OR of 4.13 (1.59 – 12.90) relative to the 1<sup>st</sup> tertile, with a significant p-for trend of 0.004.  
301 The results of the combined chemical analysis are shown in Figure 2 and Supplemental Table  
302 S2. Rhinoconjunctivitis was significantly associated with the combination of ΣTCIPP and ΣTPHP,  
303 with a “high × high” group OR of 7.14 (95% CI: 2.11 – 24.15, p=0.002).

304

#### 305 **4. Discussion**

306 In this study, we examined the association between asthma and allergies, and exposure to  
307 mixtures of phthalates and PFRs among school-age children. Statistically significant  
308 associations were observed between increased WQS index and an increased prevalence of  
309 rhinoconjunctivitis and eczema. However, in the qg-computation, no significant associations  
310 were observed between the mixture of all chemicals and any of the allergic symptoms. As for  
311 the secondary models with combinations of highly weighted chemicals, according to the qg-  
312 computation approach, the combination of “high × high” levels was yielded a significantly  
313 increased OR for rhinoconjunctivitis. To our knowledge, this is the first study to examine the  
314 associations between mixtures and combinations of phthalates and PFRs and prevalence of  
315 allergic symptoms.

316 We have measured phthalates and PFRs in house dust and their metabolites in urine,  
317 and found significant correlations between chemicals in house dust and their metabolites in  
318 urine in the same cross-sectional study (Ait Bamai et al. 2016; Bastiaensen et al. 2019). These  
319 findings suggest that house dust is a potential source of exposure to phthalates and PFRs,  
320 leading to co-exposure to both classes of chemical. In our previous study using a single  
321 chemical model, we reported that higher levels of  $\Sigma$ TCIPP were associated with increased ORs  
322 for rhinoconjunctivitis; 3-HO-TBOEP, a metabolite of TBOEP was associated with eczema (Araki  
323 et al. 2018). The findings of this study are partly in line with the previous study and provide  
324 additional insight into the combined effects of these chemicals. The two chemicals with the

325 highest weights according to the qg-computation approach may have a potential for  
326 interaction effects. For participants with rhinoconjunctivitis in this study, the positive model of  
327 WQS index, and high levels of exposure to the combination of  $\Sigma$ TCIPP and  $\Sigma$ TPHP were  
328 associated with an elevated OR.

329 In combined exposure scenarios, if the effect of one exposure is added to the effect  
330 of the second exposure, the model is additive, whereas when the effect of the second  
331 exposure is multiplied by the first exposure the model is multiplicative or synergism (Gordis  
332 1996). In this study, in comparison to the “low  $\times$  high” group and the “high  $\times$  low” group, the  
333 ORs associated with the “high  $\times$  high” group suggest the presence of additive, or effect  
334 modification in another words. When considering the ORs of (“low  $\times$  high” + “high  $\times$  low”) as  
335 a purely additive effect, and (“low  $\times$  high” \* “high  $\times$  low”) as a purely multiplicative effect. If  
336 the mode of action of phthalates and PFRs to allergic symptoms is the same, “high  $\times$  high” ORs  
337 may become similar to estimated additive effect, whereas if they have different modes of  
338 action in relation to allergic symptoms, “high  $\times$  high” ORs may become like estimated  
339 multiplicatives effect. The ORs obtained using the combination of two chemicals “high  $\times$  high”  
340 (rhinoconjunctivitis, OR = 7.14) were larger than the ORs calculated for the 3<sup>rd</sup> tertiles of single-  
341 chemical models (for rhinoconjunctivitis:  $\Sigma$ TCIPP, OR = 4.53;  $\Sigma$ TPHP, OR = 2.67, respectively,  
342 Table 3), and estimated additive (OR = 3.29) and multifpllicable (OR = 2.25) effects, respectively  
343 (Supplemental Table S2). However, it remains unclear whether the effects are additive or

344 multiplicative, as the estimated additives, multiplicatives, and “high × high” ORs were similar  
345 (Supplemental Table S2). It is also possible that several different above-mentioned properties  
346 act in parallel.

347           The evaluation of associations between mixtures or combinations of chemicals and  
348 health outcomes is a realistic approach, as phthalates and PFRs are often detected in the same  
349 samples and concentrations of each chemicals are correlated. In this study, the associations  
350 based on the qg-computation model between the mixture of all chemicals with  
351 rhinoconjunctivitis was not significant. As shown in Figure 2, some chemicals had positive  
352 weight contributions, while others had negative contributions. These positive and negative  
353 estimates cancelled each other out in the statistical models, and consequently the associations  
354 with the overall chemical mixture became not significant. However, the WQS positive model  
355 suggested an increased prevalence of rhinoconjunctivitis, as well as associations of these  
356 symptoms with the combination of the two highest chemicals. These results should not be  
357 ignored, and continuous chemical risk assessments are needed.

358           Modes of action of the observed associations of mixtures of examined chemicals with  
359 allergies remain unclear. Both phthalates and PFRs may have several different modes of action  
360 such as direct pharmacological effect on receptors involved in allergenic pathology or indirect  
361 effect as adjuvants for different causative agents to influence immune and inflammatory  
362 symptoms (Bi et al. 2018). Phthalates are suggested to have adjuvant effects on allergies, as *in*

363 *vitro* and animal studies have indicated that DEHP enhances the production of allergy-related  
364 molecules, and inflammatory cytokines such as IL-5, IL-6, and TNF- $\alpha$  (Nishioka et al. 2012;  
365 Tanaka et al. 2013). DEHP and BBzP may also increase allergy by suppressing TNF- $\alpha$  and IFN- $\beta$   
366 expression and modulate the T-cell stimulations and responses (Kuo et al. 2013). However,  
367 there are few studies on the effects of PFRs. *In vitro* studies have found that TDCIPP, TPHP  
368 and/or TBOEP have an immunocytotoxic effect, or may alter the immune response and induce  
369 oxidative stress (Canbaz et al. 2017; Killilea et al. 2017; Krivoshiev et al. 2018b). TCIPP and TCEP  
370 were found to be involved in the complement cascade along with other potent inflammatory  
371 regulators (Krivoshiev et al. 2018a). One *in vivo* study of zebrafish found that TDCIPP induced  
372 dose-response up-regulation of mRNA expression related to the receptor-centered gene  
373 networks, such as peroxisome proliferator-activated receptor alpha (PPAR- $\alpha$ ), estrogen  
374 receptors, and glucocorticoid receptors (Liu et al. 2013). Phthalate is also known to activate  
375 PPAR- $\alpha$  pathway and 8-OHdG levels (Ito et al. 2007), so that phthalate and PFRs share similar  
376 action. Recently, we found that mixtures of PFRs were positively associated with oxidative  
377 stress markers of hexanoyl-lysine, and 4-hydroxynonenal in children participating in a cross-  
378 sectional study (Ait Bamai et al. 2019). Similarly, regarding phthalates, a cross-sectional study  
379 of children revealed positive associations of phthalates with 8-hydroxy-2'-deoxyguanosine and  
380 malondialdehyde (Lee et al, 2019;Rocha et al., 2017), suggesting that phthalates and PFRs  
381 share similar properties. However, we cannot speculate on the nature of these mechanisms,

382 and even less is known for mixture effects. Another study determined that metabolites of  
383 TPHP exhibited potent oestrogen receptor (ER)  $\alpha$  and ER $\beta$  agonistic activity (Kojima et al. 2016),  
384 and that the potency of the agonistic (or antagonistic) activity differed among parent  
385 compounds and metabolites (i.e., TPHP and OH-DPHP) (Kojima et al. 2016). Both phthalates  
386 and PFRs are readily metabolised in the human body (Greaves et al. 2016; Völkel et al. 2017).  
387 But still, half-lives of chlorinated PFRs have been shown to be longer than those of, aryl- and  
388 alkyl-PFRs (Wang et al., 2020). In addition, each chemical has different renal and hepatic  
389 clearance, binding abilities with plasma proteins (Wang et al., 2020), which may result different  
390 bioactivity. Consequently, the mode of action of each individual metabolite in the human body  
391 is very complex.

392 In this study, we used standardised creatinine-corrected concentrations. These values  
393 were calculated using creatinine concentrations standardised according to sex and body size.  
394 Although many studies have used creatinine-corrected urinary metabolite levels as  
395 independent variables or the creatinine concentration as a covariate, the methods of  
396 accounting for urine dilution are still controversial. Although children comprised the target  
397 population for this study, their ages ranged from 7 to 12 years. Notably, the creatinine  
398 concentrations varied significantly among different age groups (Kruskal-Wallis test,  $p = 0.025$ )  
399 and exhibited a weak, but significant positive correlation with age (Spearman's  $\rho = 0.242$ ,  $p$   
400  $= 0.006$ ). According to Barr et al. (2005), the age group is a significant predictor of the urinary

401 creatinine concentration, and thus the creatinine-corrected concentration of an analyte  
402 should be compared with a 'reference' range derived from subjects in a similar demographic  
403 group (Barr et al. 2005). Accordingly, the individual creatinine clearance is used as the  
404 reference value when fitting the standardised creatinine corrected concentration. This enabled  
405 us to control the covariate-independent, short-term multiplicative effect of hydration on  
406 urinary dilution (O'Brien et al. 2016). At the same time, it should be noted that standardized  
407 creatinine corrected concentrations were assigned to the participants with <LOQ as well. This  
408 may modify the rank of quartiles, especially for infrequently detected metabolites such as  
409 BDCIPP, and has potential for misclassification.

410           There are some limitations to this study. First, this is a cross-sectional study and  
411 cannot be used to infer causality or the risk of developing an allergy. Moreover, the  
412 prevalence of symptoms was 2.4 times higher among the children included in this study than  
413 in the children and dwelling characteristics observed in our initial contact in 2008 (n = 4408;  
414 Table 1). Because urine samples were collected 1 or 2 years after the initial contact, children  
415 in the 1<sup>st</sup> grade were not included in this study, and low participation frequency of 2<sup>nd</sup> grade.  
416 Moreover, the dwellings were newer buildings (Ait Bamai et al. 2014), with a higher  
417 prevalence of signs of dampness (Table 1). Therefore, we must consider the potential for  
418 selection bias as calculated prevalence ratio and participation rate given by Nohr and Liew  
419 (2018) shown in Table 1, that children with allergies and a greater interest in the home

420 environment may have been more likely to choose to participate in the present study. In  
421 addition, participants with allergy symptoms may change their behaviors such as more  
422 frequent vacuuming and cleaning of their house, which may result in having lower exposures  
423 through dust to chemicals that accumulate in dust. It is notable for potential selection bias,  
424 however, it is difficult to know whether this resulted in over- or under-estimation of  
425 associations or if the direction of bias would be the same for all exposures. Second, urinary  
426 metabolites were measured only once. Both phthalates and PFRs are readily metabolised  
427 and eliminated from the body within several hours to days (Greaves et al. 2016; Völkel et al.  
428 2017). Therefore, temporal urinary metabolite concentrations may not reflect long term  
429 exposures, such as weeks or months. On the other hand, concentrations of MBzP,  $\Sigma$ TBOEP  
430 and  $\Sigma$ TCIPP were correlated with their parent compound concentrations in the house dust  
431 suggest that the potential exposure source of these compounds are housing materials (Ait  
432 Bamai et al. 2015; Bastiaensen et al. 2019). In such a case, exposure levels of BBzP and these  
433 PFRs would not vary unless the children moved or renovated their home. In addition, there  
434 may be other unmeasured exposures such as pollens and fungi, which lead to potential  
435 residual confounding. Furthermore, we observed wide confidence intervals, and may not  
436 have had enough statistical power to find significant associations, due to the relatively  
437 limited sample size; especially, the combination model that included the category of 'high x  
438 high' involved a limited number of samples. Even smaller size of each category is not enough

439 to make final conclusions of the mixture effect. Finally, the difference in the concentration  
440 levels of each chemical, nor its toxicological mechanism were considered in the statistical  
441 models. The concentrations of PFRs were lower than phthalates, whereas stronger  
442 associations with wheeze and allergic symptoms were found between PFRs than phthalates.  
443 Ginsberg and Belleggia estimated a hazard quotient for 7 chemicals in house dust using  
444 Monte Carlo methods, and found that DEHP and TDCIPP were among the 3 chemicals that  
445 stood out, showing elevated hazards (Ginsberg and Belleggia 2017). In this study, metabolites  
446 of TDCIPP, but not  $\Sigma$ DEHP, showed a high qg-computation weight. The partial consistency of  
447 this study with Ginsberg and Belleggia's hazard quotes could be due to their measured  
448 outcomes of cancer and non-cancer. Thus, the toxic constituents influencing asthma and  
449 allergy could differ. More experimental studies of the combined effect of phthalates and PFRs  
450 on allergies are warranted.

451

## 452 **5. Conclusions**

453 In this study, we examined mixtures and combined exposures to phthalates and PFRs  
454 and their association with wheeze, rhinoconjunctivitis, and eczema among elementary school-  
455 aged children. WQS analysis suggests a significant positive association of mixed exposure to  
456 phthalates and PFRs with rhinoconjunctivitis; however, these associations were not significant  
457 when using the qg-computation approach. Still, the chemicals that contributed most heavily

458 to the associations with allergies and might have exerted combined effects according to the  
459 qq-computation weights (%) included combined exposures to ΣTCIPP and ΣTPHP which were  
460 associated with increased prevalence of rhinoconjunctivitis, respectively. These preliminary  
461 findings for the associations between allergic symptoms and exposure to mixtures and  
462 combined chemicals require further studies to confirm our results.

463

#### 464 **Acknowledgments**

465 We thank all study participants and their family members. We thank Dr. Takashi Yanagawa for  
466 his advice on statistics.

467 This work was supported in part by a grant-in aid for scientific research from the Ministry of  
468 Health Labor and Welfare, Japan (H20-Kenki Ippan-009), and by the Environment Research and  
469 Technology Development Fund (5C-1151, 5-1753) of the Ministry of the Environment, Japan,  
470 and of Environmental Restoration and Conservation Agency. Michiel Bastiaensen  
471 acknowledges the partial funding of his Ph.D through the Flemish Environment and Health  
472 Study financed by the Ministry of the Flemish Community (Department of Economics, Science  
473 and Innovation; Flemish Agency for Care and Health; and Department of Environment, Nature  
474 and Energy) and through the University of Antwerp.

475

476

477 **References**

- 478 Ait Bamai, Y.; Araki, A.; Kawai, T.; Tsuboi, T.; Saito, I.; Yoshioka, E.; Cong, S.; Kishi, R. Exposure  
479 to phthalates in house dust and associated allergies in children aged 6-12years. *Environ Int*  
480 2016;96:16-23
- 481 Ait Bamai, Y.; Araki, A.; Kawai, T.; Tsuboi, T.; Saito, I.; Yoshioka, E.; Kanazawa, A.; Tajima, S.; Shi,  
482 C.; Tamakoshi, A.; Kishi, R. Associations of phthalate concentrations in floor dust and multi-  
483 surface dust with the interior materials in japanese dwellings. *Sci Total Environ* 2014;468-  
484 469:147-157
- 485 Ait Bamai, Y.; Araki, A.; Kawai, T.; Tsuboi, T.; Yoshioka, E.; Kanazawa, A.; Cong, S.; Kishi, R.  
486 Comparisons of urinary phthalate metabolites and daily phthalate intakes among japanese  
487 families. *Int J Hyg Environ Health* 2015;218:461-470
- 488 Ait Bamai, Y.; Bastiaensen, M.; Araki, A.; Goudarzi, H.; Konno, S.; Ito, S.; Miyashita, C.; Yao, Y.;  
489 Covaci, A.; Kishi, R. Multiple exposures to organophosphate flame retardants alter urinary  
490 oxidative stress biomarkers among children: The hokkaido study. *Environ Int* 2019;131:105003
- 491 Araki, A.; Bastiaensen, M.; Ait Bamai, Y.; Van den Eede, N.; Kawai, T.; Tsuboi, T.; Ketema, R.M.;  
492 Covaci, A.; Kishi, R. Associations between allergic symptoms and phosphate flame retardants in  
493 dust and their urinary metabolites among school children. *Environ Int* 2018;119:438-446
- 494 Araki, A.; Saito, I.; Kanazawa, A.; Morimoto, K.; Nakayama, K.; Shibata, E.; Tanaka, M.; Takigawa,  
495 T.; Yoshimura, T.; Chikara, H.; Saijo, Y.; Kishi, R. Phosphorus flame retardants in indoor dust  
496 and their relation to asthma and allergies of inhabitants. *Indoor Air* 2014;24:3-15
- 497 Ballesteros-Gómez, A.; Erratico, C.A.; Eede, N.V.d.; Ionas, A.C.; Leonards, P.E.G.; Covaci, A. In  
498 vitro metabolism of 2-ethylhexyldiphenyl phosphate (ehdphp) by human liver microsomes.  
499 *Toxicol Lett* 2015;232:203-212
- 500 Barr, D.B.; Wilder, L.C.; Caudill, S.P.; Gonzalez, A.J.; Needham, L.L.; Pirkle, J.L. Urinary  
501 creatinine concentrations in the u.S. Population: Implications for urinary biologic monitoring  
502 measurements. *Environ Health Perspect* 2005;113:192-200
- 503 Bastiaensen, M.; Bamai, Y.A.; Araki, A.; Van den Eede, N.; Kawai, T.; Tsuboi, T.; Kishi, R.; Covaci,  
504 A. Biomonitoring of organophosphate flame retardants and plasticizers in children: Associations  
505 with house dust and housing characteristics in japan. *Environ Res* 2019;
- 506 Beasley, R. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis,  
507 and atopic eczema: Isaac. *The Lancet* 1998;351:1225-1232
- 508 Bekö, G.; Callesen, M.; Weschler, C.J.; Toftum, J.; Langer, S.; Sigsgaard, T.; Høst, A.; Kold Jensen,  
509 T.; Clausen, G. Phthalate exposure through different pathways and allergic sensitization in  
510 preschool children with asthma, allergic rhinoconjunctivitis and atopic dermatitis. *Environ Res*  
511 2015;137:432-439
- 512 Benjamin, S.; Masai, E.; Kamimura, N.; Takahashi, K.; Anderson, R.C.; Faisal, P.A. Phthalates  
513 impact human health: Epidemiological evidences and plausible mechanism of action. *J Hazard*  
514 *Mater* 2017;340:360-383

515 Bi, C.; Maestre, J.P.; Li, H.; Zhang, G.; Givehchi, R.; Mahdavi, A.; Kinney, K.A.; Siegel, J.; Horner,  
516 S.D.; Xu, Y. Phthalates and organophosphates in settled dust and hvac filter dust of u.S. Low-  
517 income homes: Association with season, building characteristics, and childhood asthma. *Environ*  
518 *Int* 2018;121:916-930

519 Bornehag, C.; Sundell, J.; Weschler, C.; Sigsgaard, T.; Lundgren, B.; Hasselgren, M.; Hagerhed-  
520 Engman, L. The association between asthma and allergic symptoms in children and phthalates  
521 in house dust: A nested case-control study. *Environ Health Perspect* 2004;112:1393 - 1397

522 Callesen, M.; Bekö, G.; Weschler, C.J.; Langer, S.; Brive, L.; Clausen, G.; Toftum, J.; Sigsgaard, T.;  
523 Høst, A.; Jensen, T.K. Phthalate metabolites in urine and asthma, allergic rhinoconjunctivitis  
524 and atopic dermatitis in preschool children. *Int J Hyg Environ Health* 2014;217:645-652

525 Canbaz, D.; Logiantara, A.; van Ree, R.; van Rijt, L.S. Immunotoxicity of organophosphate flame  
526 retardants tphp and tdcipp on murine dendritic cells in vitro. *Chemosphere* 2017;177:56-64

527 Canbaz, D.; van Velzen, M.J.M.; Hallner, E.; Zwinderman, A.H.; Wickman, M.; Leonards, P.E.G.;  
528 van Ree, R.; van Rijt, L.S. Exposure to organophosphate and polybrominated diphenyl ether  
529 flame retardants via indoor dust and childhood asthma. *Indoor Air* 2016;26:403-413

530 Carrico, C.; Gennings, C.; Wheeler, D.C.; Factor-Litvak, P. Characterization of weighted quantile  
531 sum regression for highly correlated data in a risk analysis setting. *J Agr Biol Environ St*  
532 2015;20:100-120

533 Gennings, C.; Sabo, R.; Carney, E. Identifying subsets of complex mixtures most associated with  
534 complex diseases: Polychlorinated biphenyls and endometriosis as a case study. *Epidemiology*  
535 2010;21 Suppl 4:S77-84

536 Ginsberg, G.L.; Belleggia, G. Use of monte carlo analysis in a risk-based prioritization of toxic  
537 constituents in house dust. *Environ Int* 2017;109:101-113

538 Gordis, L. *Epidemiology* 5th edition. Elsevier; Amsterdam, the Netherlands: 2013

539 Greaves, A.K.; Su, G.; Letcher, R.J. Environmentally relevant organophosphate triesters in herring  
540 gulls: In vitro biotransformation and kinetics and diester metabolite formation using a hepatic  
541 microsomal assay. *Toxicol Appl Pharmacol* 2016;308:59-65

542 Ito, Y.; Yamanoshita, O.; Asaeda, N.; Tagawa, Y.; Lee, C.-H.; Aoyama, T.; Ichihara, G.; Furuhashi,  
543 K.; Kamijima, M.; Gonzalez, F.J.; Nakajima, T. Di(2-ethylhexyl)phthalate induces hepatic  
544 tumorigenesis through a peroxisome proliferator-activated receptor  $\alpha$ -independent  
545 pathway. *J Occup Health* 2007;49:172-182

546 James, R.A.; Hertz-Picciotto, I.; Willman, E.; Keller, J.A.; Charles, M.J. Determinants of serum  
547 polychlorinated biphenyls and organochlorine pesticides measured in women from the child  
548 health and development study cohort, 1963-1967. *Environ Health Perspect* 2002;110:617-624

549 Just, A.C.; Whyatt, R.M.; Miller, R.L.; Rundle, A.G.; Chen, Q.; Calafat, A.M.; Divjan, A.; Rosa, M.J.;  
550 Zhang, H.; Perera, F.P.; Goldstein, I.F.; Perzanowski, M.S. Children's urinary phthalate  
551 metabolites and fractional exhaled nitric oxide in an urban cohort. *Am J Respir Crit Care Med*  
552 2012;186:830-837

553 Kajiwara, N.; Noma, Y.; Takigami, H. Brominated and organophosphate flame retardants in  
554 selected consumer products on the japanese market in 2008. *J Hazard Mater* 2011;192:1250-  
555 1259

556 Kanazawa, A.; Saito, I.; Araki, A.; Ma, M.; Saijo, Y.; Kishi, R. Association between indoor exposure  
557 to semi-volatile organic compounds and building-related symptoms among the occupants of  
558 residential dwellings. *Indoor Air* 2010;20:72-84

559 Keil, A.P.; Buckley, J.P.; O'Brien, K.M.; Ferguson, K.K.; Zhao, S.; White, A.J. A quantile-based g-  
560 computation approach to addressing the effects of exposure mixtures. *arXiv:190204200 [statME]*  
561 2019;

562 Killilea, D.W.; Chow, D.; Xiao, S.Q.; Li, C.; Stoller, M.L. Flame retardant tris(1,3-dichloro-2-  
563 propyl)phosphate (tdcpp) toxicity is attenuated by n-acetylcysteine in human kidney cells.  
564 *Toxicol Rep* 2017;4:260-264

565 Kishi, R.; Araki, A.; Minatoya, M.; Hanaoka, T.; Miyashita, C.; Itoh, S.; Kobayashi, S.; Ait Bamai,  
566 Y.; Yamazaki, K.; Miura, R.; Tamura, N.; Ito, K.; Goudarzi, H. The hokkaido birth cohort study  
567 on environment and children's health: Cohort profile—updated 2017. *Environ Health Prev Med*  
568 2017;22:46

569 Kishi, R.; Saijo, Y.; Kanazawa, A.; Tanaka, M.; Yoshimura, T.; Chikara, H.; Takigawa, T.; Morimoto,  
570 K.; Nakayama, K.; Shibata, E. Regional differences in residential environments and the  
571 association of dwellings and residential factors with the sick house syndrome: A nationwide  
572 cross-sectional questionnaire study in japan. *Indoor Air* 2009;19:243-254

573 Kojima, H.; Takeuchi, S.; Van den Eede, N.; Covaci, A. Effects of primary metabolites of  
574 organophosphate flame retardants on transcriptional activity via human nuclear receptors.  
575 *Toxicol Lett* 2016;245:31-39

576 Krivoshiev, B.V.; Beemster, G.T.S.; Sprangers, K.; Blust, R.; Husson, S.J. A toxicogenomics approach  
577 to screen chlorinated flame retardants tris(2-chloroethyl) phosphate and tris(2-chloroisopropyl)  
578 phosphate for potential health effects. *J Appl Toxicol* 2018a;38:459-470

579 Krivoshiev, B.V.; Beemster, G.T.S.; Sprangers, K.; Cuypers, B.; Laukens, K.; Blust, R.; Husson, S.J.  
580 Toxicogenomics of the flame retardant tris (2-butoxyethyl) phosphate in hepg2 cells using rna-  
581 seq. *Toxicol In Vitro* 2018b;46:178-188

582 Ku, H.Y.; Su, P.H.; Wen, H.J.; Sun, H.L.; Wang, C.J.; Chen, H.Y.; Jaakkola, J.J.K.; Wang, S.-L.;  
583 Group, T. Prenatal and postnatal exposure to phthalate esters and asthma: A 9-year follow-up  
584 study of a taiwanese birth cohort. *PLoS One* 2015;10:e0123309

585 Kuo, C.-H.; Hsieh, C.-C.; Kuo, H.-F.; Huang, M.-Y.; Yang, S.-N.; Chen, L.-C.; Huang, S.-K.; Hung,  
586 C.-H. Phthalates suppress type i interferon in human plasmacytoid dendritic cells via epigenetic  
587 regulation. *Allergy* 2013;68:870-879

588 Lee, I.; Alakeel, R.; Kim, S.; Al-Sheikh, Y.A.; Al-Mandeel, H.; Alyousef, A.A.; Kho, Y.; Choi, K.  
589 Urinary phthalate metabolites among children in saudi arabia: Occurrences, risks, and their  
590 association with oxidative stress markers. *Sci Total Environ* 2019;654:1350-1357

591 Liu, C.; Wang, Q.; Liang, K.; Liu, J.; Zhou, B.; Zhang, X.; Liu, H.; Giesy, J.P.; Yu, H. Effects of  
592 tris(1,3-dichloro-2-propyl) phosphate and triphenyl phosphate on receptor-associated mrna  
593 expression in zebrafish embryos/larvae. *Aquat Toxicol* 2013;128-129:147-157

594 Luongo, G.; Östman, C. Organophosphate and phthalate esters in settled dust from apartment  
595 buildings in stockholm. *Indoor Air* 2016;26:414-425

596 Mage, D.T.; Allen, R.H.; Kodali, A. Creatinine corrections for estimating children's and adult's  
597 pesticide intake doses in equilibrium with urinary pesticide and creatinine concentrations. *J*  
598 *Expo Sci Environ Epidemiol* 2008;18:360-368

599 Meek, M.E.; Boobis, A.R.; Crofton, K.M.; Heinemeyer, G.; Raaij, M.V.; Vickers, C. Risk assessment  
600 of combined exposure to multiple chemicals: A who/ipcs framework. *Regul Toxicol Pharmacol*  
601 2011;

602 Nishioka, J.; Iwahara, C.; Kawasaki, M.; Yoshizaki, F.; Nakayama, H.; Takamori, K.; Ogawa, H.;  
603 Iwabuchi, K. Di-(2-ethylhexyl) phthalate induces production of inflammatory molecules in  
604 human macrophages. *Inflammation Res* 2012;61:69-78

605 Nohr, E.A. and Liew L.; How to investigate and adjust for selection bias in cohort studies. *Acta*  
606 *Obstetricia et Gynecologica Scandinavica* 2018;97:407–416

607 O'Brien, K.M.; Upson, K.; Cook, N.R.; Weinberg, C.R. Environmental chemicals in urine and blood:  
608 Improving methods for creatinine and lipid adjustment. *Environ Health Perspect* 2016;124:220-  
609 227

610 Rocha, B.A.; Asimakopoulos, A.G.; Barbosa, F., Jr.; Kannan, K. Urinary concentrations of 25  
611 phthalate metabolites in brazilian children and their association with oxidative DNA damage.  
612 *Sci Total Environ* 2017a;586:152-162

613 Rocha, B.A.; Asimakopoulos, A.G.; Barbosa, F.; Kannan, K. Urinary concentrations of 25 phthalate  
614 metabolites in brazilian children and their association with oxidative DNA damage. *Sci Total*  
615 *Environ* 2017b;586:152-162

616 Romano, M.E.; Eliot, M.N.; Zoeller, R.T.; Hoofnagle, A.N.; Calafat, A.M.; Karagas, M.R.; Yolton, K.;  
617 Chen, A.; Lanphear, B.P.; Braun, J.M. Maternal urinary phthalate metabolites during  
618 pregnancy and thyroid hormone concentrations in maternal and cord sera: The home study. *Int*  
619 *J Hyg Environ Health* 2018;221:623-631

620 Saijo, Y.; Kishi, R.; Sata, F.; Katakura, Y.; Urashima, Y.; Hatakeyama, A.; Kobayashi, S.; Jin, K.;  
621 Kurahashi, N.; Kondo, T.; Gong, Y.Y.; Umemura, T. Symptoms in relation to chemicals and  
622 dampness in newly built dwellings. *Int Arch Occup Environ Health* 2004;77:461-470

623 Stapleton, H.M.; Klosterhaus, S.; Eagle, S.; Fuh, J.; Meeker, J.D.; Blum, A.; Webster, T.F. Detection  
624 of organophosphate flame retardants in furniture foam and u.S. House dust. *Environ Sci Technol*  
625 2009;43:7490-7495

626 Tanaka, M.; Inoue, K.-i.; Momoi, T.; Takano, H. In vivo immunoamplifying effects of di-(2-  
627 ethylhexyl) phthalate on cytokine response. *Immunopharmacol Immunotoxicol* 2013;35:147-150

628 Völkel, W.; Fuchs, V.; Wöckner, M.; Fromme, H. Toxicokinetic of tris(2-butoxyethyl) phosphate

629 (tboep) in humans following single oral administration. Arch Toxicol 2017;  
630 van den Eede, N.; Dirtu, A.C.; Neels, H.; Covaci, A. Analytical developments and preliminary  
631 assessment of human exposure to organophosphate flame retardants from indoor dust. Environ  
632 Int 2011;37:454-461  
633 Wang, X.; Liu, Q.; Zhong, W.; Yang, L.; Yang, J.; Covaci, A.; Zhu, L. Estimating renal and hepatic  
634 clearance rates of organophosphate esters in humans: Impacts of intrinsic metabolism and  
635 binding affinity with plasma proteins. Environ Int 2019;134:105321  
636 Whyatt, R.M.; Perzanowski, M.S.; Just, A.C.; Rundle, A.G.; Donohue, K.M.; Calafat, A.M.; Hoepner,  
637 L.A.; Perera, F.P.; Miller, R.L. Asthma in inner-city children at 5-11 years of age and prenatal  
638 exposure to phthalates: The columbia center for children's environmental health cohort. Environ  
639 Health Perspect 2014;122:1141-1146  
640

**Table 1.** Characteristics of the participants.

		This study (n=128)		Primary questionnaire survey (n=4408)		prevalence ratio <sup>a)</sup>	participation rate <sup>b)</sup> (%)
		n	%	%			2.9
Sex	boys	68	53.1	1.1	48.1	1.1	3.2
	girls	60	46.9	0.9	49.6	0.9	2.7
Grade	2	14	10.9	0.0	16.4	0.0	0.0
	3	35	27.3	0.7	16.7	0.7	1.9
	4	27	21.1	1.6	17.0	1.6	4.7
	5	24	18.8	1.2	17.4	1.2	3.5
	6	28	21.9	1.2	15.8	1.2	3.4
Height (cm) (mean ± standard deviation)		137.3 ± 8.82		No information			
Weight (kg) (mean ± standard deviation)		32.1 ± 6.44		No information			
Annual household income (Japanese yen/year)	< 3 million	6	4.7				
	3-5 million	25	19.5				
	5-8 million	50	39.1				
	>8 million	28	21.9				
	missing	19	14.8				
Dampness index at home (mean ± SD)		2.10 ± 1.25		1.04 ± 1.03			
	≤1	39	30.5	0.5	65.9	0.5	1.3
	≥2	89	69.5	2.0	34.0	2.0	5.9
Wheeze	yes	29	22.7	2.4	9.3	2.4	7.1
Rhinoconjunctivitis	yes	47	36.7	2.4	15.4	2.4	6.9
Eczema	yes	36	28.1	2.4	11.7	2.4	7.0

642 <sup>a)</sup>, Prevalence rate = prevalence in this study (%) / prevalence in primary questionnaire survey (%)643 <sup>b)</sup>, Participation rate (%) = 2.9 \* prevalence rate

**Table 2.** Distribution of phthalates and PFR metabolites in urine.

nM	n	>DL (%)	min	25%tile	50% tile	75% tile	max
ΣDBP	128	96.7	<LOQ	98.4	236	759	31500
MBzP	128	78.1	<LOQ	27.6	62.9	124	6310
ΣDEHP	128	100.0	82.3	265	442	631	29100
5-HO-EHDPHP	113	80.0%	<LOQ	0.05	0.11	0.24	3.05
BDCIPP	128	55.3%	<LOQ	<LOQ	0.20	0.29	10.2
DNBP	113	8.3%	<LOQ	<LOQ	<LOQ	<LOQ	3.69
TCEP	113	85.2%	<LOQ	0.10	0.19	0.36	1.13
ΣTBOEP	128	99.2%	<LOQ	1.08	1.88	4.29	15.1
ΣTCIPP	128	95.3%	<LOQ	0.62	0.95	2.29	42.0
ΣTPHP	128	83.6%	<LOQ	1.41	2.13	3.65	23.4
creatinine (µg/mL)	128	100%	69.9	802	1010	1430	2750
standardised creatinine corrected concentrations (nmol/g Standardised Cr.)							
ΣDBP			11.0	78.0	184	537	34700
MBzP			3.68	23.5	52.8	106	2620
ΣDEHP			58.5	179	330	512	20300
5-HO-EHDPHP			0.01	0.05	0.08	0.16	4.72
BDCIPP			0.03	0.08	0.13	0.26	6.83
TCEP			0.02	0.08	0.15	0.27	2.39
ΣTBOEP			0.14	0.77	1.63	3.40	15.2
ΣTCIPP			0.10	0.48	0.77	1.82	37.9
ΣTPHP			0.59	1.28	1.69	2.78	27.4

644 BDCIPP, bis(1,3-dichloro-2-propyl) phosphate; ΣDBP, dibutyl phthalate; ΣDEHP, di(2-ethylhexyl) phthalate; DL, detection  
645 limit; DNBP dimethyl phosphate, 5-HO-EHDPHP, 5-hydroxyethylhexyldiphenyl phosphate; MBzP, monobenzyl phthalate;  
646 ΣTBOEP, Σ metabolites of tris(2-butoxyethyl) phosphate; ΣTCIPP, Σ metabolites of tris(1-chloro-iso-propyl) phosphate;  
647 TCEP, tris(2-chloroethyl) phosphate; ΣTPHP, Σ metabolites of triphenyl phosphate  
648 ΣDBP (MnBP and MiBP), ΣDEHP (MEHP, MEOHP, and MECPP), ΣTBOEP (BBOEP, 3-HO-TBOEP, and BBOEHP), ΣTCIPP  
649 (BCIPP and BCIPHIPP), ΣTPHP (DPHP and 4-HO-DPHP)  
650

**Table 3.** Associations between allergic symptoms and chemical mixture.

	OR	95%CI		p-value		
Weighted quantile sum regression model						
Positive models						
Wheeze	1.52	0.67	3.50	0.315		
Rhinoconjunctivitis	2.60	1.38	5.14	0.004		
Eczema	1.91	0.99	3.85	0.060		
Inverse models						
Wheeze	0.96	0.83	1.79	0.109		
Rhinoconjunctivitis	0.58	0.29	1.12	0.110		
Eczema	0.54	0.24	1.18	0.131		
Quantile g-computation model						
	OR	95%CI		p-value	Sum of positive coefficient	Sum of negative coefficient
Wheeze	0.95	0.33	2.70	0.918	1.23	-1.28
Rhinoconjunctivitis	1.29	0.49	3.40	0.612	1.76	-1.51
Eczema	1.00	0.37	2.72	0.996	0.77	-0.78

652 Adjusted for sex, grade, annual household income and dampness index

653 OR, odds ratio; CI, confidence interval

654

**Table 4.** Single chemicals categorised into tertiles, and associations with allergic symptoms.

Allergic symptom	metabolites	1st		OR	2nd			n	OR	3rd			trend P-value	
		n	ref		n	95%CI	P-value			n	95%CI	P-value		
<b>Wheeze</b>														
	ΣDBP	43	ref	43	0.83	0.29	2.37	0.724	42	0.48	0.15	1.54	0.217	0.223
	MBzP	43	ref	43	0.29	0.08	1.10	0.069	42	1.20	0.41	3.48	0.737	0.703
	ΣDEHP	43	ref	43	0.83	0.26	2.59	0.745	42	0.75	0.23	2.37	0.620	0.623
	5-HO-EHDPHP	38	ref	38	2.43	0.70	8.43	0.162	37	3.21	0.86	11.89	0.082	0.082
	BDCIPP	45	ref	48	1.21	0.40	3.69	0.731	35	1.25	0.39	4.03	0.712	0.706
	uTCEP	38	ref	38	1.95	0.59	6.40	0.273	37	1.61	0.46	5.61	0.457	0.434
	ΣTBOEP	43	ref	43	0.89	0.28	2.81	0.846	42	1.33	0.43	4.13	0.627	0.630
	ΣTCIPP	43	ref	43	0.88	0.30	2.58	0.816	42	0.56	0.18	1.78	0.327	0.332
	ΣTPHP	43	ref	43	1.02	0.33	3.20	0.972	42	1.64	0.53	5.05	0.392	0.395
<b>Rhinoconjunctivitis</b>														
	ΣDBP	43	ref	43	1.39	0.53	3.61	0.502	42	0.84	0.32	2.24	0.731	0.733
	MBzP	43	ref	43	1.18	0.45	3.12	0.736	42	0.88	0.33	2.36	0.799	0.787
	ΣDEHP	43	ref	43	1.64	0.61	4.39	0.328	42	1.09	0.40	2.99	0.864	0.870
	5-HO-EHDPHP	38	ref	38	0.59	0.21	1.64	0.310	37	1.06	0.39	2.91	0.910	0.951
	BDCIPP	45	ref	48	<b>2.95</b>	<b>1.04</b>	<b>8.37</b>	<b>0.042</b>	35	<b>2.93</b>	<b>1.04</b>	<b>8.28</b>	<b>0.043</b>	<b>0.045</b>
	uTCEP	38	ref	38	0.50	0.18	1.41	0.189	37	1.37	0.48	3.88	0.558	0.642
	ΣTBOEP	43	ref	43	1.69	0.63	4.58	0.299	42	2.11	0.75	5.91	0.157	0.160
	ΣTCIPP	43	ref	43	1.31	0.46	3.73	0.614	42	<b>4.53</b>	<b>1.59</b>	<b>12.90</b>	<b>0.005</b>	<b>0.004</b>
	ΣTPHP	43	ref	43	1.67	0.60	4.63	0.322	42	2.67	0.97	7.36	0.057	0.056
<b>Eczema</b>														
	ΣDBP	43	ref	43	1.09	0.39	3.06	0.875	42	0.69	0.24	2.02	0.501	0.506
	MBzP	43	ref	43	0.38	0.12	1.16	0.088	42	0.83	0.29	2.36	0.726	0.741
	ΣDEHP	43	ref	43	4.91	1.47	16.48	0.010	42	2.92	0.82	10.37	0.098	0.131
	5-HO-EHDPHP	38	ref	38	1.58	0.49	5.08	0.446	37	2.59	0.79	8.46	0.116	0.115
	BDCIPP	45	ref	48	1.29	0.43	3.82	0.652	35	1.96	0.66	5.84	0.225	0.223
	uTCEP	38	ref	38	0.63	0.21	1.92	0.417	37	0.79	0.25	2.47	0.681	0.642
	ΣTBOEP	43	ref	43	0.70	0.22	2.19	0.538	42	1.85	0.63	5.42	0.260	0.220
	ΣTCIPP	43	ref	43	0.90	0.30	2.66	0.847	42	1.03	0.36	2.96	0.954	0.942
	ΣTPHP	43	ref	43	1.02	0.35	2.92	0.973	42	1.11	0.38	3.25	0.846	0.845

655

Odds ratio (95% CI) is calculated by logistic regression.

656

Adjusted for sex, grade, annual income and dampness index

657

Statistically significant (p<0.05) is shown in bold.

658

BDCIPP, bis(1,3-dichloro-2-propyl) phosphate; ΣDBP, dibutyl phthalate; ΣDEHP, di(2-ethylhexyl) phthalate; DL, detection limit; DNBP dimethyl phosphate, 5-HO-EHDPHP, 5-hydroxyethylhexyldiphenyl

659

phosphate; MBzP, monobenzyl phthalate; ΣTBOEP, Σ metabolites of tris(2-butoxyethyl) phosphate; ΣTCIPP, Σ metabolites of tris(1-chloro-iso-propyl) phosphate; TCEP, tris(2-chloroethyl) phosphate; ΣTPHP, Σ

660

metabolites of triphenyl phosphate

35

661 **Figure legend**

662 **Figure 1.** Weight of each chemical according to quantile g-computation regression.

663 (A) Wheeze, (B) Rhinoconjunctivitis, (C) Eczema.

664 BDCIPP, bis(1,3-dichloro-2-propyl) phosphate;  $\Sigma$ DEHP, di(2-ethylhexyl) phthalate; 5-HO-EHDPHP, 5-hydroxy-

665 2-ethylhexyl diphenyl phosphate; MBzP, monobenzyl phthalate;  $\Sigma$ TBOEP, tris(2-butoxyethyl) phosphate;

666  $\Sigma$ TCIPP, tris(1-chloro-iso-propyl) phosphate; TCEP, tris(2-chloroethyl) phosphate;  $\Sigma$ TPHP, triphenyl phosphate.

667  $\Sigma$ DBP (MnBP and MiBP),  $\Sigma$ DEHP (MEHP, MEOHP, and MECPP),  $\Sigma$ TBOEP (BBOEP, 3-HO-TBOEP, and BBOEHP),

668  $\Sigma$ TCIPP (BCIPP and BCIPHIPP), and  $\Sigma$ TPHP (DHPH and 4-HO-DHPH).

669


670 **Figure 2** Associations between combinations of  $\Sigma$ TCIPP and  $\Sigma$ TPHP with rhinoconjunctivitis

671 The odds ratios (ORs) and 95% confidence intervals (95% CI) of the rhinoconjunctivitis are shown as black  
672 squares and whiskers, respectively for TCIPP and  $\Sigma$ TPHP. The levels of each chemical were categorised as  
673 “high” or “low”, with the “high” cutoff as follows:  $\Sigma$ TCIPP,  $\geq 1.30$  nM/g Standardised-Cr.;  $\Sigma$ TPHP,  $\geq 2.29$  nM/g  
674 Standardised-Cr. The ORs were calculated with the “low X low” group as the reference category, and  
675 adjusted for sex, grade, annual household income, dampness index. The X-axis indicates, from left: L X L,  
676 low X low; L X H, Low-High; H X L, high X low; and H X H, high X high. The Y-axis indicates OR (95% CI). \*\*P  
677 <0.01


678 CI, confidence interval; Cr., creatinine; OR, odds ratio;  $\Sigma$ TCIPP,  $\Sigma$  metabolites of tris(1-chloro-iso-propyl)

679 phosphate in urine;  $\Sigma$ TPHP,  $\Sigma$  metabolites of triphenyl phosphate in urine.

(A) Wheeze



(B) Rhino-conjunctivitis



(C) Eczema




Figure 1 Weight of each chemical according to quantile g-computation regression.

680

681




Figure 2 Associations between combinations of ΣTCIPP and ΣTPHP with rhinoconjunctivitis

683 Supplemental Material

684 **Combined exposures to phthalate esters and phosphate flame retardants and plasticizers and**  
686 **their association with wheeze and allergy symptoms among school children**

687  
688 Atsuko Araki<sup>a</sup>, Yu Ait Bamai<sup>a</sup>, Michiel Bastiaensen<sup>b</sup>, Nele Van den Eede<sup>b</sup>, Toshio Kawai<sup>c</sup>, Tazuru  
689 Tsuboi<sup>c</sup>, Chihiro Miyashita<sup>a</sup>, Sachiko Itoh<sup>a</sup>, Houman Goudarzi<sup>d, e</sup>,  
690 Satoshi Konno<sup>e</sup>, Adrian Covaci<sup>b</sup>, Reiko Kishi<sup>a\*</sup>

691  
692  
693 Table of contents

694  
695 **Supplemental Table S1** Correlations between chemicals measured in urine

696  
697 **Supplemental Table S2** Distribution of phthalates and PFR metabolites in urine in ng/mL

698  
699 **Supplemental Table S3** Combined chemicals and their associations with allergic symptoms

**Supplemental Table S1.** Correlations between chemicals measured in urine.

	ΣDBP	MBzP	Σ3DEHP	5-HO-EHDPHP	BDCIPP	TCEP	ΣΤΒΟΕΡ	ΣΤCIPP	ΣΤΡHP
ΣDBP	1.000	0.148	0.013	0.054	0.139	0.066	0.010	0.084	0.134
MBzP		1.000	0.138	0.209*	0.047	0.068	0.128	0.148	0.100
Σ3DEHP			1.000	0.300*	0.216*	-0.122	0.087	0.200*	0.340**
5-HO-EHDPHP				1.000	0.271**	-0.018	0.325**	0.455**	0.624**
BDCIPP					1.000	0.094	-0.013	0.081	0.340**
TCEP						1.000	-0.018	0.080	0.052
ΣΤΒΟΕΡ							1.000	0.074	0.251**
ΣΤCIPP								1.000	0.334**
ΣΤΡHP									1.000

Spearman's rho, \*P <0.05, \*\*P <0.01

700

701

**Supplemental Table 2.** Distribution of phthalates and PFR metabolites in urine in ng/mL.

ng/mL	n	>DL (%)	min	25%tile	50% tile	75% tile	max
MBzP	128	78.1	<LOQ	7.2	16.1	31.7	1620
5-HO-EHDPHP	113	80.0%	<LOQ	0.02	0.04	0.09	1.2
BDCIPP	128	55.3%	<LOQ	<LOQ	0.07	0.09	3.3
DNBP	113	8.3%	<LOQ	<LOQ	<LOQ	<LOQ	0.78
TCEP	113	85.2%	<LOQ	0.03	0.05	0.10	0.32

702

703

704

**Supplemental Table S2.** Combined chemicals and their associations with allergic symptoms.

	Ref (Low×Low)		Low × High			High × Low				High × High				Additive OR (L × H) + (H × L)	Multiplicative OR (L × H) * (H × L)	
	n	n	OR	95%CI	P-value	n	OR	95%CI	P-value	n	OR	95%CI	P-value			
Rhino-conjunctivitis																
ΣTCIPP and ΣTPHP	63	23	0.97	0.29 3.19	0.959	23	2.32	0.75 7.13	0.142	19	<b>7.14</b>	<b>2.11 24.15</b>	<b>0.002</b>	3.29	2.25	

OR (95%CI) were calculated by logistic regression model adjusted for sex, grade, annual income and dampness index

Statistically significant (p<0.05) shown in bold.

705

706